These drugs could be repurposed for alleviation of (iCAF-derived) IL-6 mediated immunosuppression in solid malignancies, which has been demonstrated to act synergistically with PD-L1 blockade in a murine model of melanoma [116]. The gene discussed is CD274; the disease is melanoma.